Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.27.762320

Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients

Baechle, J. J.·Arthur, J.·Nguyen, K.·Wu, F.·Fuentealba, M.·Knowlton, K. U.·Knight, S.·Horne, B.·Sayed, N.·Maecker, H.·Winer, D. A.·Barzilai, N.·Davis, M. M.·Haddad, F.·Furman, D.
View original source ↗Export metadata ↓

Abstract

Despite advances in clinical care, cardiovascular disease (CVD) remains the leading cause of disability and mortality worldwide. While age alone is a primary risk factor for CVD, accumulating evidence suggests the immune system influences the initiation and progression of CVD pathophysiology, particularly in heart failure with preserved ejection fraction (HFpEF) and atherosclerotic CVD (ASCVD). Here, using two independent cohorts of older adults, we develop a thirty-protein signature of age based on serum immune proteomics, which correlates with HFpEF and ASCVD risk and mortality (Immuno-Proteomic Age of Cardiovascular Etiology, iPACE). We find aging-related circulating immune proteins associated with ASCVD and HFpEF-specific resilience and susceptibility that may be used as potential prognostic, diagnostic, or therapeutic targets.

Explore related subjects

immunologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Baechle, J. J., Arthur, J., Nguyen, K., Wu, F., Fuentealba, M., Knowlton, K. U., Knight, S., Horne, B., Sayed, N., Maecker, H., Winer, D. A., Barzilai, N., Davis, M. M., Haddad, F., Furman, D.. 2026-11-02. Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients. https://doi.org/10.64898/2026.10.27.762320

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy is unknown. Here, using EBV B-cell sequencing (EBV-seq), we profiled EBV+ B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV+ B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV+ B cells and shifted the reconstituted repertoire towards IgM+, minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV+ B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro, EBV+ B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV+ autoreactive B-cell repertoire contributes to sustained drug-free remission.

immunology↗
bioRxiv2026

A minimal two-residue C-terminal truncation of AID in adult-onset hyper-IgM syndrome type 2 (HIGM2)

Activation-induced cytidine deaminase (AID), encoded by AICDA, facilitates class-switch recombination (CSR) and somatic hypermutation (SHM) in activated B cells. Loss of AID function causes hyper-IgM syndrome type 2 (HIGM2). While typically autosomal recessive, three C-terminal truncation variants have been reported to act in autosomal dominant manner. We describe a novel heterozygous AICDA nonsense variant, c.589G>T (p.G197*), that truncates the final two C-terminal residues of AID and results in adult-onset HIGM2. Single-cell sequencing of primary patient B cells revealed a complete block in CSR and a [~]10-fold reduction in SHM. AICDA mRNA expression was balanced between wild-type and variant alleles, yet AID protein abundance was reduced to [~]56% with normal subcellular localization. Remarkably, inducible germinal center (iGB) cultures restored CSR in purified naive patient B cells. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB platform can rescue B cells harboring heterozygous, but not homozygous, AICDA variants. These results demonstrate that even a two-amino-acid truncation at the AID C-terminus is sufficient to disrupt its function and cause HIGM2.

immunology↗
bioRxiv2026

Foreign Body Responses Adapt to Systemic Immunosuppression to Maintain Local Immune Homeostasis Through Decorin-Associated Signaling

Foreign body responses (FBRs) involve complex interactions between pro- and anti-inflammatory signals that regulate the integration and function of implanted biomaterials. However, most mechanistic studies of FBRs have been conducted in healthy hosts, and little is known about how these immune responses are regulated under pathological conditions. Here, we investigated immune responses to porous polycaprolactone (PCL) scaffold implants in mice with endotoxin tolerance or aggressive breast tumors, which induce systemic immunosuppression through distinct mechanisms. Despite suppressed inflammatory activity in major organs, implanted scaffolds maintained locally immune-active environments characterized by increased pro-inflammatory immune-cell populations and elevated inflammatory mediators, including CXCL1. In migration assays, CXCL1 preferentially recruited neutrophils and enriched immune-cell populations with pro-inflammatory phenotypes among splenocytes derived from both endotoxin-tolerant and tumor-bearing mice. The extracellular matrix proteoglycan decorin, a damage-associated molecular pattern with TLR2/4-activating activity in myeloid cells, was enriched within scaffolds but reduced in major organs under both immunosuppressive conditions. Recombinant decorin promoted pro-inflammatory phenotypes in suppressive myeloid-cell populations and enhanced CXCL1 production through TLR2/4-associated signaling, suggesting a mechanistic link between decorin-mediated myeloid activation, CXCL1-dependent immune-cell recruitment, and the maintenance of local immune activity at biomaterial interfaces. Together, these findings reveal that FBRs are not merely passive inflammatory reactions to biomaterial implants but can dynamically adapt to systemic immune dysfunction to sustain local immune homeostasis. This intrinsic immunoregulatory capacity may represent an additional factor influencing the performance of immunomodulatory implants and should be considered in biomaterial design to optimize therapeutic outcomes across different applications and host immune conditions.

immunology↗